1C
GTHX

1623 Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

1623 Capital’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,432
Closed -$207K – 81
2021
Q2 		$207K Buy
9,432
+2,694
+40% +$59.8K 0.08% 70
2021
Q1 		$162K Buy
+6,738
New +$157K 0.07% 60

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

1623 Capital's GTHX Position: Q3 2021 in Review

1623 Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2021, closing a stake of 9,432 shares — an estimated $207K sold.

1623 Capital first reported a position in GTHX in Q1 2021 and held it in 2 quarters. The position peaked at $207K in Q2 2021. 115 funds tracked by Wall St. Rank hold GTHX as of Q3 2021.

  • 1623 Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • 1623 Capital sold 9,432 G1 Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $207K.
  • 1623 Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • 1623 Capital's G1 Therapeutics, Inc. Common Stock position peaked at $207K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2021.

Based on 1623 Capital's 13F filing for Q3 2021, filed 12 Nov 2021.